We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

By LabMedica International staff writers
Posted on 16 Sep 2014
A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.

Modularity is the key concept defining the new Leica Microsystems (Wetzlar, Germany) DMi8 inverted microscope, and the core of this concept is the unique illumination port, the "Infinity Port." This port facilitates the integration of additional light sources and laser systems for advanced applications.

To augment the Infinity Port, the Leica DMi8 boasts an innovative closed-loop focus system accurate to 20 nm over a 12 mm travel range, which enables researchers to scan large specimens with high precision.

Modules available for use with the DMi8 allow the user to take advantage of the full range of contrast methods from brightfield, integrated modulation contrast, phase contrast to darkfield, differential interference contrast, and fluorescence. More...


Use of different analysis channels for different fluorescence stains allows the user to analyze several aspects of a sample at the same time. An individual workflow can be assigned to each analysis channel. For example a binary reference mask can be applied to obtain object specific data, such as counting the number of spots in each nucleus. Alternatively, multiple analysis channels can be applied to the same image. Healthy cells can be counted on a stained color image in one analysis channel while a second analysis channel is used to count abnormal cells.

"The Leica DMi8 is an open and freely configurable inverted research microscope which meets the current and future needs of life scientists in a single platform," said Bernard Kleine, product manager at Leica Microsystems. "Universality and individuality have been the heart of our development work. With the Leica DMi8 we serve customer needs ranging from plain microscopy to advanced research applications, and pay heed to the fact that tasks and applications in research change. The Leica DMi8 combines the versatility of an open platform with the user-friendliness of a system solution."

Related Links:

Leica Microsystems



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Clinical Informatics Platform
CLARION™
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.